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1. Scientific abstract 
Background: Molecular prescreening of tumors aims at selecting populations that 
can benefit most from anticancer targeted-agents. Breast cancer present several 
molecular alterations, such as PIK3CA mutations, PTEN low expression, or FGFR 
amplification or mutation.  
Purpose: Assess the activity of single agent PI3K/AKT/mTOR pathway inhibitors 
(PI3Kpi) in metastatic breast cancer (MBC) patients, and explore PI3K pathway 
alterations as a predictor of clinical benefit to these agents.  
Patients and Methods: From September 2009 to November 2012, MBC patients 
were assessed for PI3K pathway alterations. Some were treated with single agent 
pan-isoform PI3K, alpha-specific PI3K, dual PI3K/mTORC1/2, mTORC1/2, or AKT 
inhibitors. Their outcomes were analyzed.  
Results: Of 445 patients tested, 38 received single agent PI3Kpi. Prevalence of 
molecular alterations: PIK3CA mutation 59.4%, AKT1 mutation 13.3%, PTEN low 
29.7%, PI3K/AKT/mTOR pathway dysregulation (PIK3CA mutation and/or AKT1 
mutation and/or PTEN low) 85.7%. Subtype distribution: HR+/HER2- 76.3%, 
HER2+ 13.2%, TN 10.5%. Median number of prior MBC lines: 5 (1-11). Median 
time to progression (TTP) was 2.6 months (95%CI 2.0-4.8), being numerically 
longer in PIK3CA WT patients (4.1 vs. 2.3 months, p=NS). Among PIK3CA-
mutated patients, those receiving a PI3K-alpha inhibitor did better than those 
treated with pan-isoform PI3K inhibitor (P=0.025).  
Conclusion: Single agent PI3K pathway inhibitors showed interesting activity in 
heavily pre-treated MBC patients. In general, there was no correlation between 
PIK3 pathway alterations and efficacy of these agents, but PIK3CA mutated 
patients did better with PI3K alpha-specific inhibitors. These results emphasize the 
need of an adequate molecular selection prior to targeted therapy in MBC. 
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2. Background 
Breast cancer is the most frequently diagnosed cancer worldwide and the leading 
cause of cancer death among females, accounting for 23% of the total cancer 
cases and 14% of total cancer deaths (1). A large proportion of breast cancer 
cases, especially in developed countries, are now diagnosed in early stages, but 
25-40% of patients will eventually develop recurrence or metastases (2). 
Additionally, 5-6% of patients will have overt metastatic disease at presentation (3). 
Metastatic breast cancer (MBC) is generally an incurable condition, with a median 
survival that ranges from 2 to 3 years after diagnosis (4). A better understanding of 
the molecular pathways involved in the pathogenesis of breast cancer has 
prompted the development and use of novel agents in the treatment of this 
disease. The paradigmatic example is the development of extremely effective anti-
HER2 therapies in the last 15 years, which has dramatically changed the natural 
history of HER2-positive breast cancer (5-7). However, for triple negative MBC no 
specific targeted agents have been approved, and for ER-positive MBC overall 
survival has remained stable since the early nineties (8). 
Personalized cancer therapy refers to the use of molecular characteristics of the 
tumor and microenvironment, as well as characteristics of the patient, in order to 
tailor therapies delivered to the patient, and treat cancer more effectively and with 
less toxicity (9). Routine molecular screening of primary and/or metastatic tumors 
is now used as part of prescreening programs to enrich phase I or early phase II 
trials with specific populations (10-12). This effort aims at selecting the populations 
that can potentially benefit most from anticancer targeted-agents. Successful 
histories of such matching include, among others, vemurafenib for B-RAF V600E 
mutant melanoma (13), crizotinib for non-small cell lung tumors with EML4-ALK 
translocation (14), and imatinib for KIT-mutated gastrointestinal stromal tumors 
(15). 
The phosphatydilinositol-3-kinase/AKT/mammalian target of rapamicin 
(PI3K/AKT/mTOR) intracellular signaling pathway is frequently dysregulated in 
human cancer (16). In breast cancer, the most common alterations of this pathway 
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are mutations of PIK3CA (the gene encoding for the catalytic p110α subunit of 
PI3K, 10-40% depending on breast cancer subtype) and PTEN low expression 
(~50%) (17). Additionally, amplification of FGFR1 occurs in approximately 10% of 
breast cancers (18-19), and AKT1 mutation can occur in about 3% of ER+ breast 
cancers (16). Of note, with the increasingly widespread use of high-throughput 
platforms, new potential targetable molecular alterations are expected to be 
identified in the future. 
Several agents targeting PI3K/AKT/mTOR pathway alterations at different levels 
are currently in clinical development. They include PI3K inhibitors (either pan-
isoform PI3K, alpha-specific PI3K inhibitors, or others), dual PI3K/mTORC1/2 
inhibitors, mTORC1/2 inhibitors, or AKT inhibitors (20-23). Although the rationale 
for targeting these alterations in breast cancer is very appealing, no compelling 
evidence has been provided so far that MBC patients with tumors harboring 
targetable molecular aberrations definitely benefit from matched targeted agents. 
A pre-screening program for detection of PI3K/AKT/mTOR pathway alterations in 
MBC patients receiving active treatment for advanced disease was initiated in 
September 2009 at the Medical Oncology Department and Breast Cancer Group of 
Vall d’Hebron University Hospital (24). Information on PIK3CA and PTEN status 
became available for the treating physician contemporaneously to decision-making 
on treatment, and some of these patients were offered treatment with a 
PI3K/AKT/mTOR pathway inhibitor in some point of their MBC natural history. 
The aim of this study was to assess the clinical activity of several PI3K pathway 
inhibitors when used as single agent in MBC patients. We also wanted to explore 
the presence of PI3K pathway alterations, such as PIK3CA mutations, AKT1 
mutations, and/or PTEN low expression, as a predictor of clinical benefit to these 
agents in the clinical setting. 
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3. Materials and Methods 
i) Mutation analysis of PIK3CA and determination of PTEN  
From September 2009 to February 2011, somatic mutation profiling of PIK3CA was 
performed using the PCR-based DxS Mutation Test Kit (Qiagen®). DxS PI3K 
Mutation Test Kit is an assay for detection of 4 specific mutations in the PIK3CA 
gene (H1047R, E542K, E545D and E545K) using real-time PCR, and was used 
according to the manufacturer’s protocol. 
From February 2011 to November 2012, the MassARRAY system (Sequenom®) 
and OncoCartaTM v1.0 assay panel were implemented for routine molecular testing 
of tumor samples at our Institution. This panel performs somatic mutation profiling 
of 238 mutations in 19 oncogenes (including PIK3CA, KRAS, BRAF or EGFR). The 
panel is based on the use of IPlex chemistry (Sequenom). In brief, DNA was 
extracted from 5x10μm slices of formalin fixed paraffin-embedded (FFPE) tumor 
samples using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion). Six-
hundred nanograms (ng) of DNA were used for mutation profiling using OncoCarta 
v1.0. After quantification (nanodrop) and dilution of DNA to a 10ng/μl 
concentration, multiplexed PCR was performed in order to amplify the genomic 
regions that contain the loci to be genotyped. Each mutation was then analyzed as 
the single-base extension product of a probe that anneals immediately contiguous 
to the mutation position. Gen II SpectroCHIPs were loaded into a matrix-assisted 
laser desorption/ionization–time of flight (MALDI-TOF) mass spectrometer (Mass 
ARRAY, Sequenom) and spectra were obtained for each of the extension 
products. Data analysis and mutation reports were generated using the Typer 
Analyzer 4.0 software (Sequenom). Manual assessing of spectra was performed 
on each of the PIK3CA assays included in the panel for all samples as well as on 
all reported mutations by the Sequenom software. A mutation call was done in the 
presence of >10% mutate alleles in a given sample. 
PTEN was determined by immunohistochemistry. The antibody anti-PTEN  from 
Cell Signaling Technologies® (Clone 138G6, cat# 9559, batch 7-12) was used in a 
1:100 diluted incubated at room temperature for 60 minutes. An H-score was 
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calculated based on the intensity of staining (0-3) and percentage of staining-
positive cells (0-100). PTEN low expression was considered when H-score was ≤ 
50 (0-300). PTEN null was assumed in case of absence of immunostaining (as 
compared with the internal control). 
ii) Patients 
MBC patients treated from September 2009 to November 2012 with single agent 
pan-isoform PI3K inhibitors, PI3K-alpha specific inhibitors, dual PI3K/mTORC1/2 
inhibitors, mTORC1/2 inhibitors or AKT inhibitors in early drug development trials 
at the Vall d’Hebron University Hospital in Barcelona were identified. Patients were 
included in the analysis if tumor tissue was available for molecular testing. They 
provided signed informed consent to the molecular determinations as part of the 
routine molecular testing at our Institution. 
If PIK3CA mutation, and/or AKT1 mutation, and/or PTEN low were present, 
patients were classified as having a PI3K pathway dysregulation. If neither of the 
alterations was present, they were classified as having no pathway dysregulation. 
Patients with wild type (WT) PIK3CA / AKT1 and PTEN not determined, or patients 
with PTEN normal and PIK3CA / AKT1 not assessed, were considered as having a 
non-informative PI3K pathway. 
Registration of the patients in the database, pathology assessments, molecular 
determinations and treatment were all performed at Vall d’Hebron University 
Hospital. Medical charts of all patients were reviewed to confirm the accuracy of 
the variables recorded in the database. Patients’ demographics, tumor 
characteristics, characteristics of the metastatic disease at the time of beginning of 
treatment with PI3K pathway inhibitor, outcome of the treatment and vital status, 
including date of death or last follow-up, were collected and recorded for each 
patient. 
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iii) Treatment and evaluation 
Data on type of inhibitor – pan-isoform PI3K, PI3K-alpha specific, dual 
PI3K/mTORC1/2, mTORC1/2 or AKT – and dose of PI3K pathway inhibitor – lower 
or higher than 2/3 of the declared maximum tolerated dose (MTD) – were collected 
for each individual patient. 
All efficacy and safety assessments were done according to each protocol. 
Generally, this included physical examination, evaluation of adverse events and 
laboratory work-up at baseline and at least prior to the beginning of each cycle of 
treatment. Tumor assessments were done for all patients at baseline and every 
other cycle later on (between 6 and 8 weeks depending on the length of cycles at 
each different clinical trial). Response was assessed according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) v.1.0 (23) and reported as the best 
response. Complete response (CR) was defined as disappearance of all  lesions; 
partial response (PR) as a reduction of at least 30% respect to the baseline sum of 
target lesions without evidence of appearance of new lesions; progressive disease 
(PD) as at least a 20% increase in the sum of largest diameters of target lesions, 
taking as reference the smallest sum of largest diameters recorded since the 
treatment started, or appearance of unequivocal new lesions; stable disease (SD) 
as neither sufficient decrease in sum of largest diameters to qualify for PR nor 
sufficient increase in sum of largest diameters to qualify for PD. 
Response rate (RR) was defined as the proportion of patients with CR or PR, and 
clinical benefit rate (CBR) as the proportion of patients with a CR, PR or SD lasting 
≥6 months.  
Treatment was continued until progressive disease or presence of unacceptable 
toxicity, and the reason for discontinuation was collected and recorded. 
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iv) Statistical analysis 
This is a retrospective analysis using data from several prospective clinical trials. 
Time to progression (TTP) was defined as the time (in months) from the date of 
beginning PI3K pathway inhibitor until the date of recording progressive disease. 
Patients who interrupted treatment for toxicity and did not progress thereafter or 
patients that were on treatment at the time of data cut-off were censored for the 
purpose of the TTP analysis. 
Overall survival (OS) after beginning of PI3K pathway inhibitor (OSPI3Kpi) was 
calculated from the date of beginning of experimental treatment until the date of 
death or last follow-up. OS after MBC diagnosis (OSMBC) was defined from the 
date of first distant recurrence after completion of loco-regional therapy to the date 
of death or last follow-up. 
All the statistical analysis was performed with the R x64 3.0.0 platform. Survival 
package of the R-library was used for the survival analysis (TTP and OS). Survival 
times were compared by the log-rank test. 
Univariate analysis was performed to compare clinical characteristics according to 
distinct molecular alterations. Logistic regression model was used to estimate the 
effect (OR) and AUC to measure the predictive ability of the variable. 
Comparison of times within the same patient was performed using the Wilcoxon 
non-parametric test. 
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4. Results 
i) Patients 
From September 2009 to November 2012, 523 MBC patients were screened for 
the presence of PIK3CA mutations and PTEN alterations at our Hospital (Figure 1). 
From these, 78 could not be assessed because of insufficient material, leaving a 
total of 445 patients with at least one molecular determination available. 
Of these 445 patients, 115 (25.8%) had PIK3CA mutation and 115 (25.8%) had 
PTEN low.  
Thirty-eight out of the 445 patients (8.5%) were treated with single agent PI3K 
pathway inhibitor, meeting the inclusion criteria for this study. 
 
Figure 1: Disposition of patients included in the analysis. PI3Kpi, PI3K pathway inhibitor. 
 
Patients’ characteristics are shown in Table 1. Of note, the majority had 
HR+/HER2- tumors, visceral disease and were heavily pre-treated, with a median 
number of 5 lines of treatment for metastatic disease (range 1-11). 
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Table 1. Patients’ characteristics. 
Demographical or Clinical Characteristic N (%) 
Age, years  
      Mean (SD) 55 (10.8) 
      Median (Range) 54 (36-78) 
Tumor subtype  
      HER2+ 5 (13.2%) 
      HR+/HER2- 29 (76.3%) 
      Triple Negative 4 (10.5%) 
Number of metastatic sites  
      Median (Range) 2 (1-6) 
      1-2 20 (52.6%) 
      ≥3 18 (47.4%) 
Sites of metastasis  
      Bone only 1 (2.6%) 
      Visceral 37 (97.4%) 
Prior lines for MBC treatment  
      Median (Range) 5 (1-11) 
      Prior Chemotherapy for MBC 33 (86.8%) 
Dose of PI3K pathway inhibitor  
<2/3 MTD 4 (10.5%) 
≥2/3 MTD 34 (89.5%) 
HR, hormonal receptor; MBC, metastatic breast cancer; MTD, maximum tolerated dose; SD, standard 
deviation. 
 
Table 2 details the molecular features of this population. 
Determinations were performed mainly in primary tumor tissue (n=21, 55.3%), but 
metastatic tumor tissue was used to assess PI3K pathway alterations in 13 
patients (34.2%). 
PIK3CA status could be determined in 32 out of the 38 patients. Of these, 19 had a 
PIK3CA mutation (59.4%), mainly in exon 20 (n=10). 
PTEN expression could be determined in 37 out of the 38 patients, and 11 had 
PTEN low expression (29.7%). 
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Table 2. Molecular determinations.  
Site of molecular determination N (%) 
Primary tumor 21 (55.3%) 
Metastasis 13 (34.2%) 
Unknown 4 (10.5%) 
Analysis with Sequenom technology 15 (39.5%) 
PIK3CA status (N=32)  
WT 13 (40.6%) 
Mutated 19 (59.4%) 
Exon 1 
E110K 
 
1 (5.3%) 
Exon 9 
E545K 
Q546K 
 
6 (31.6%) 
2 (10.5%) 
Exon 20 
H1047R 
 
10 (52.6%) 
PTEN (N=37)  
      Normal 26 (70.3%) 
      Low 11 (29.7%) 
Other PI3K pathway alterations (N=15)  
AKT1 E17K mutation 2 (13.3%) 
PI3K pathway dysregulation (N=38)  
      No 5 (13.2%) 
      Yes 30 (78.9%) 
Non-informative 3 (7.9%) 
WT, wild type. 
Sequenom technology was performed in 15 patients (39.5%), allowing for 
screening of other mutations. From these, 2 (13.3%) had an AKT1 mutation (both 
E17K). 
PI3K pathway status was non-informative in 3 patients (PTEN normal, PIK3CA not 
determined). Among the remaining 35 patients, 30 (78.9%) had a dysregulation in 
the PI3K pathway (2 patients had both PIK3CA mutation and PTEN low 
expression, and 2 patients had AKT1 mutation). 
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Distribution of molecular alterations (PIK3CA mutation, PTEN low expression, and 
PI3K pathway dysregulation) did not associate with age, breast cancer subtype, or 
number of metastatic sites (AUC<0.72 for all comparisons, univariate analysis NS). 
Table 3 shows the distribution of type of treatment according to PIK3CA status. 
One third of the patients were treated with pan-isoform PI3K inhibitors, 25.7% with 
AKT inhibitors, 18.4% with PI3K-alpha specific inhibitor, 18.4% with dual 
PI3K/mTORC1/2, and 7.9% with AKT inhibitors. Of note, the majority of PIK3CA 
mutated patients received a PI3K-alpha specific inhibitor. 
 
Table 3. Type of inhibitor received, according to PIK3CA status. 
Type of Inhibitor 
PIK3CA WT 
N=13 
PIK3CA MUT 
N=19 
PIK3CA ND 
N=6 
Total 
N=38 
Pan-isoform PI3K 4 (30.8%) 5 (26.3%) 3 (50%) 12 (31.6%) 
PI3K-alpha specific - 7 (36.8%) - 7 (18.4%) 
Dual PI3K/mTORC1/2 2 (15.4%) 4 (21.1%) 1 (16.7%) 7 (18.4%) 
mTORC1/2 3 (23.0%) - - 3 (7.9%) 
AKT 4 (30.8%) 3 (15.8%) 2 (33.3%) 9 (25.7%) 
Total 13 (100%) 19 (100%) 6 (100%) 38 (100%) 
MUT, mutated; ND, not done; WT, wild type. 
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ii) Time to progression 
Figure 2 depicts TTP for the individual patients, as well as the type of breast tumor 
and the distribution of molecular alterations. 
Interestingly, seven patients received treatment with no evidence of progression for 
more than 6 months. 
 
 
Figure 2. TTP for each individual patient. 
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Median TTP with the treatment with a PI3K pathway inhibitor as single agent was 
2.6 months (95%CI 2.0-4.8 months). 
No differences in TTP were seen according to age, breast tumor subtype or 
previous number of MBC lines (Table 4). 
Table 4. Median TTP according to clinical characteristics. 
TTP (95%CI)  P 
Overall 2.6 (2.0-4.8) 
Age   
<50 2.5 (1.8-4.8) 
0.225 
>=50 3.8 (2.0-NR) 
Breast tumor subtype   
HR+/HER2- 2.1 (1.9-4.8) 
0.745 HER2+ 5.9 (2.3-NR) 
TN 3.6 (2.0-NR) 
Previous number of MBC lines   
0-1 1.9 (1.2-NR) 0.685 
≥2 2.6 (1.0-4.9)  
CI, Confidence Interval; HR, Hormonal Receptor; NR, Not Reached; TN, Triple negative. 
TTP to PI3K pathway inhibitor was numerically (but not statistically significantly) 
higher in PIK3CA WT patients (4.1 vs. 2.3 months, P=0.500), and in patients with 
no PI3K pathway dysregulation (4.9 vs. 2.3 months, P=0.374) (Table 5 and Figure 
3). Interestingly, no differences were seen according to PTEN. 
Table 5. Time to progression to PI3K pathway inhibitor and to prior line of treatment. 
Time in months Prior line of treatment PI3K pathway inhibitor 
 TTP (95%CI) P TTP (95%CI) P 
Overall 5.0 (3.6 - 9.9) 2.6 (2.0 - 4.8) 
PIK3CA   
   WT 5.1 (3.4 - NR) 
0.829 
4.1 (2.4 - NR) 
0.500 
   Mutated 5.7 (3.1 - 13.1) 2.3 (1.9 - 7.3) 
PTEN   
   Low 4.1 (3.3 - NR) 
0.507 
2.4 (1.9 - NR) 
0.480 
   Normal 5.3 (3.9 - 11.7) 2.9 (2.0 - 7.3) 
PI3K pathway dysregulation   
   No 12.3 (3.6 - NR) 
0.411 
4.9 (4.1 - NR) 
0.374 
   Yes 4.1 (3.3 - 7.2) 2.3 (1.9 - 5.9) 
CI, Confidence Interval; NR, Not Reached; TTP, Time to Progression; WT, Wild Type. 
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Figure 3. Time to Progression to PI3K pathway inhibitor. (A) Overall population. (B) According to PIK3CA 
mutation. (C) According to PTEN expression. (D) According to PI3K pathway dysregulation. TTP, Time to 
progression. 
 
When we look at how the PI3K pathway inhibitor as single agent compared to the 
prior treatment these patients had received (Table 5), we see that in all subgroups 
prior treatment led to significantly longer TTP than PI3K inhibitor as single agent 
(p<0.001 for all comparisons). 
Finally, we repeated all the analysis excluding those patients that received a PI3K 
inhibitor in first or second line of treatment for MBC, in order to see how PI3K 
inhibitor as single agent behaved in a population that currently has no approved 
standard treatment for MBC. This has left us with 33 patients, whose clinical 
characteristics were similar to the general population. 
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Molecular characteristics of these patients are shown in Table 6. Determinations 
were performed mainly in primary tumor tissue (n=18, 54.6%), and metastatic 
tumor tissue was used in 11 patients (33.3%). 
Table 6. Molecular characteristics of patients treated in third or posterior lines for metastatic breast 
cancer.  
Site of molecular determination (N=33)  
Primary tumor 18 (54.6%) 
Metastasis 11 (33.3%) 
Unknown 4 (12.1%) 
Analysis with Sequenom technology (N=33) 13 (39.4%) 
PIK3CA status (N=28)  
WT 11 (39.3%) 
Mutated 17 (60.7%) 
Exon 1 
E110K 
 
1 (5.8%) 
Exon 9 
E545K 
Q546K 
 
6 (35.3%) 
2 (11.8%) 
Exon 20 
H1047R 
 
8 (47.1%) 
PTEN (N=32)  
      Normal 23 (71.9%) 
      Low 9 (28.1%) 
Other PI3K pathway alterations (N=13)  
AKT1 E17K mutation 2 (15.4%) 
PI3K pathway dysregulation (N=30)  
      No 4 (13.3%) 
      Yes 26 (86.7%) 
WT, wild type. 
PIK3CA status could be determined in 28 out of the 33 patients. Of these, 17 had a 
PIK3CA mutation (60.7%), mainly in exon 20 (n=8). PTEN expression could be 
determined in 32 out of the 33 patients, and 9 had PTEN low expression (28.1%). 
Sequenom technology was performed in 13 of the 33 patients (39.4%), allowing for 
screening of other mutations. From these, 2 (15.4%) had an AKT1 mutation (both 
E17K). 
PI3K pathway status was non-informative in 3 patients. Among the remaining 30 
patients, 26 (86.7%) had a dysregulation in the PI3K pathway. 
In this selected population of patients, TTP was 2.6 months overall (95%CI 2.0-
4.9), and again it was numerically (but not statistically significantly) higher in 
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PIK3CA WT patients (4.9 vs. 2.3 months, P=0.202), and in patients with no PI3K 
pathway dysregulation (6.1 vs. 2.4 months, P=0.276) (Table 7 and Figure 4). 
Table 7: Time to progression to PI3K pathway inhibitor and to prior line of treatment in patients 
receiving PI3K pathway inhibitor in 3rd or posterior line. 
Time in months Prior line of treatment PI3K pathway inhibitor 
 TTP (95%CI) p TTP (95%CI) p 
Overall 5.0 (3.6-11.7) 2.6 (2.0-4.9) 
PIK3CA     
WT 4.0 (3.4-NR) 
0.743 
4.9 (2.4-NR) 
0.202 
Mutated 5.5 (3.1-13.1) 2.3 (1.9-7.3) 
PTEN     
Low 4.1 (3.28-NR) 
0.374 
3.2 (1.9-NR) 
0.918 
Normal 5.1 (3.6-12.5) 2.6 (2.0-7.3) 
PI3K pathway dysregulation     
No 12.3 (3.6-NR) 
0.474 
6.1 (3.4-NR) 
0.276 
Yes 4.1 (3.1-9.9) 2.4 (1.9-7.3) 
NR, Not Reached; WT, Wild Type. 
 
Figure 4. Time to Progression to PI3K pathway inhibitor in patients receiving PI3K pathway inhibitor in 
3
rd
 or posterior line. (A) Overall population. (B) According to PIK3CA mutation. (C) According to PTEN 
expression. (D) According to PI3K pathway dysregulation. 
Treball de Fi de Màster Oficial Investigaciò Clínica Aplicada en Ciències de la Salut 
Ana Mafalda Antunes de Melo e Oliveira  20 
 
Prior treatment led to significantly longer TTP than PI3K inhibitor as single agent in 
all subgroups (p<0.001 for all comparisons) (Table 7). 
It has been suggested that PIK3CA mutation predicts response to PI3K alpha-
specific inhibitors, but probably not to pan-isoform PI3K, dual PI3K/mTOR, mTOR, 
or AKT inhibitors. To test this hypothesis, we had a look at the outcomes of the 19 
patients with a PIK3CA mutation in our population. Seven out of these 19 patients 
(36.8%) received an alpha-specific inhibitor (Table 8). 
Table 8. Distribution of patients with PIK3CA mutations according to treatment received. 
Type of Treatment N 
Alpha-specific PI3K inhibitor  
Pan-isoform PI3K inhibitor 
7 
5 
Alpha-specific PI3K inhibitor 
Pan-isoform PI3K, dual PI3K/mTOR, mTOR, AKT inhibitor 
7 
12 
Notably, patients with PIK3CA mutation that receive a PI3K-alpha inhibitor did 
better than patients with PIK3CA mutation that receive a pan-isoform PI3K inhibitor 
(P=0.025) (Figure 5). A numerical difference was also seen when comparing 
treatment with alpha-specific inhibitor with other treatments (3.2 vs. 1.7 months), 
although it did not reach statistical significance (P=0.520). 
 
Figure 5. TTP in PIK3CA mutated patients. (A) Treatment with pan-isoform PI3K inhibitor versus treatment 
with PI3K alpha-specific inhibitor. (B) Treatment with PI3K alpha-specific inhibitor versus treatment with other 
inhibitors (pan-isoform PI3K, dual PI3-mTOR, mTORC1/2, and AKT inhibitors). 
  
1.2 vs. 3.2 months, P=0.025  
 
3.2 vs. 1.7 months, P=0.520 
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iii) Response to treatment 
Table 9 shows the overall response rate of these patients.  
Table 9. Response rate in the overall population. 
Best response N (%) 
CR - 
PR 1 (2.6%) 
SD 22 (57.9%) 
PD 15 (39.5%) 
SD > 6 months 7 (18.4%) 
CBR 8 (21.1%) 
CBR, clinical benefit rate; CR, complete response; PD, progressive disease; PR, partial response; SD, stable 
disease. 
Twenty-nine of the 38 patients (76.3%) had measurable disease according to 
RECIST 1.0.  Figure 6 shows the waterfall plot for these patients. One PR was 
recorded (RR 2.6%), in an ER+/HER2- patient with a PIK3CA mutation in exon 9, 
and 19 patients had SD as best response. 
 
Figure 6. Waterfall plot of best response to treatment. 
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Of the nine patients who had non-measurable disease only, three achieved stable 
disease as best response (one of them >6 months) and the remaining had 
progressive disease at the time of first tumor assessment. 
No clear association between response and PIK3CA status, PTEN expression or 
presence of a PI3K pathway dysregulation could be established. 
iv) Exploratory analysis of survival 
In the whole population, median OS after receiving a PI3K pathway inhibitor was 
20.1 months (95%CI 8.5-NR). No statistically different results were observed 
according to the presence of PIK3CA mutation, or expression of PTEN, although 
patients with PI3K pathway dysregulation lived less than patients with no PI3K 
pathway dysregulation after having received the PI3K pathway inhibitor (Figure 7). 
 
Figure 7. Overall Survival after treatment with PI3K pathway inhibitor. (A) Overall population. (B) 
According to PIK3CA mutation. (C) According to PTEN expression. (D) According to PI3K pathway 
dysregulation. NR, Not Reached. 
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Median OS after diagnosis of MBC was 58.1 months (Figure 8). Although patients 
with PIK3CA mutations had a shorter OS after diagnosis of MBC, this did not reach 
statistical significance (p=0.704). 
 
Figure 8. Overall Survival after diagnosis of metastatic breast cancer. (A) Overall population. (B) 
According to PIK3CA mutation. (C) According to PTEN expression. (D) According to PI3K pathway 
dysregulation. NR, Not Reached. 
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5. Discussion 
The prevalence of PIK3CA mutations and PTEN low expression in our cohort was 
59.4% and 20.7%, respectively, for a total of 78.9% of patients with a dysregulation 
in the PI3K pathway. These numbers are slightly higher than the usually reported 
in breast cancer (16, 17). This may be due to a twofold selection bias: the one 
introduced by treating physicians that offered a pathway-modulating agent to 
patients with PI3K pathway dysregulation (especially to patients harboring a 
PI3KCA mutation); or the bias of clinical trials that specifically required patients 
with molecular alterations as inclusion criteria. 
This is, to the best of our knowledge, the largest cohort of breast cancer patients 
treated with single agent PI3K pathway inhibitors that has been reported to date. 
In our cohort, the TTP to single agent PI3K pathway inhibitor was 2.6 months, 
considering both patients treated in any line and only heavily pre-treated MBC 
patients (i.e. patients who received the PI3K pathway inhibitor in ≥3rd line). While 
the majority of our patients had a non-clinically significant benefit from this 
treatment (52.6% had TTP of ≤2 months), it is remarkable that 8 achieved a PR or 
SD for more than 6 months (CBR of 21%). This is an interesting result for a single-
agent targeted therapy in a refractory setting population. However, median TTP to 
single agent PI3K pathway inhibitor in the whole cohort was consistently inferior 
that median TTP to the prior line of treatment these patients had received (p<0.01 
for all comparisons). 
It has been speculated that PI3K pathway inhibitors may have limited clinical 
activity if used as single agents, because of the complex network of negative 
feedback loops involving receptor tyrosine kinases (RTK) and PI3K/AKT/mTOR 
and MAPK pathways (26). Examples of this feedback loops are the rebound 
phosphorylation of AKT after inhibition of TORC1 and S6K with everolimus (27, 
28), the enhanced transcription and phosphorylation of multiple RTKs (including 
HER3, IGFR-1 and insulin receptor) after AKT inhibition (29), and the 
compensatory activation of the ERK signaling pathway as a result of activation of 
HER family receptors upon inhibition of p110 (30). For those patients who did not 
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benefit from single agent treatment, we can hypothesize that some of these 
feedback loops were being activated, leading to the lack of response. Analyzing 
tumor samples after tumor progression to these agents would clearly help us 
understand if these mechanisms of resistance might be involved. Combinatorial 
approaches involving PI3K/AKT/mTOR inhibitors, MAPK pathway inhibitors and/or 
other standard treatments such as anti-hormonal therapy, chemotherapy or anti-
HER2 therapy have been or are currently being explored as a way of overcoming 
such mechanisms of resistance (31-33).  
PIK3CA mutations and/or PTEN low expression have been proposed as 
biomarkers of response to PI3K pathway inhibitors (34-38). In our cohort, no clear 
association between TTP and PIK3CA or PTEN status could be demonstrated. 
However, among PIK3CA mutated patients, those who were treated with PI3K 
alpha-specific inhibitors had longer TTP than those who received pan-isoform PI3K 
inhibitors. Although very preliminary, this is the first time such an observation is 
made in the clinical setting. Given this possibility, the identification of a PIK3CA 
mutation may prompt the treating physician to offer these patients an alpha-specific 
inhibitor. Recently, a trial testing single agent BYL719, a selective inhibitor of 
PI3Kα, reported prolonged disease stabilization in patients with ER+/PIK3CA 
mutated breast cancer and one out of the 11 breast cancer patients achieved a 
partial response (38). Results from this and other trials with alpha isoform-specific 
inhibitors will be important to determine their activity in PIK3CA mutated MBC 
patients. 
The suggestion that patients harboring a PIK3CA mutation may have worse 
outcomes when treated with single agent PI3K pathway inhibitors is provocative. 
However, it should be interpreted cautiously, as the retrospective design of the 
study and the small numbers of patients preclude adequate powered comparisons 
between groups. Of note, our results contrast to another study reporting a 
response rate of 30% in gynecological and breast cancer patients with PIK3CA 
mutations, compared with 10% in those without a mutation enrolled in similar trials 
(p=0.04) (39). It should be stressed that in this study all responses were seen in 
patients receiving combination therapies (44% vs. 0% for single agents, p=0.06), 
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while in our study all patients received PI3K pathway inhibitors as single agents. 
Additionally, in the study by Janku et al. most of the responding patients received a 
combination of an mTOR inhibitor with liposomal doxorubicin (an effective 
chemotherapy in breast and gynecological tumors) and among the 7 patients 
achieving PR, only one had breast cancer. 
Establishing a valid predictive biomarker of response to PI3K/AKT/mTOR inhibitors 
in the clinical setting can be challenging for a number of reasons. First, the 
molecular alterations we are able to detect may be “passenger”, and not true 
drivers of tumor proliferation. Second, the presence of a single mutation may not 
be a sufficient biomarker of pathway activation, and hence of potential benefit of a 
drug that targets the pathway. Loi et al. for instance, have described that PIK3CA 
mutations in ER+/HER2- are associated with relatively low mTORC1 signaling 
output, which correlated with rapamycin resistance (40). This kind of signatures 
may traduce more accurately the activation of the PI3K/AKT/mTOR pathway and 
hence may help to discriminate for treatment sensitivity. Finally, the presence of 
the biomarker may not be representative of the current disease. In our study, all 
the molecular determinations were performed in archival specimens, and the 
majority (55.3%) was tissue from the primary tumor. This may lead to two major 
limitations when looking for a predictive biomarker. The first is due to tumor 
heterogeneity, as a single biopsy in a single time point may not traduce the 
molecular complexity of the tumor (41, 42). The second is the possibility of clonal 
evolution between archival tumor (primary) specimens and the contemporary 
metastatic disease. Of note, it is estimated that about 25% of breast cancers 
change their PIK3CA status along the natural history of the disease (43, 44). 
Ideally, fresh tumor biopsies from target lesions prior to treatment beginning should 
be obtained, but this must balance against several safety and ethical issues (45). 
This work presents other limitations that must be acknowledged. First, we have 
included outcomes from compounds acting in the PI3K signaling pathway at 
different sites, and we cannot exclude that their activity is neither equivalent nor 
comparable. Then, accuracy and sensitivity of PIK3CA somatic mutation 
determinations vary between techniques, and we cannot rule out that other 
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important predictive mutations were not detected by the technology that was used 
for most of the current analysis. It is also uncertain which the best technique to 
determine PTEN activity is. We have used an H-score ≤50 to consider the 
presence of a deficient PTEN, as it was the required cut-off for the inclusion in 
several of the considered clinical trials, but this is probably an approximate way of 
measuring PTEN function, and a threshold decided without a sound biological 
rationale. 
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6. Conclusion 
In conclusion, treatment with single agent PI3K pathway inhibitors showed an 
interesting activity in a population of heavily pre-treated MBC patients. Correlation 
between PIK3 pathway alterations and efficacy of these agents in the general 
population could not be demonstrated, but patients harboring a PIK3CA mutation 
did better if treated with a PI3K alpha-specific inhibitor. These results emphasize 
the need of an adequate molecular selection prior to beginning of a targeted 
therapy in MBC. 
Expanding the knowledge on the activity of alpha isoform-specific PI3K inhibitors in 
MBC patients, discovery of innovative biomarkers of response and development of 
rational combinations of PI3K pathway inhibitors with standard treatments are 
warranted to improve outcome of MBC patients, to overcome treatment resistances 
and to optimize the use of these targeted drugs. 
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